Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Peter Maccallum Cancer Institute has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, showing a level of diversification in the prosecution of their portfolio. This spread indicates that the institute's current patent applications are being evaluated by different technical specialists across multiple departments, rather than being concentrated under a single reviewer.
KAUR, GURPREET is the busiest examiner, currently managing 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, each examiner is responsible for 1 action. This distribution across 3 distinct art units suggests that the institute's current patent challenges are spread across multiple specialized technical groups. For the institute, this means that prosecution strategies must be tailored to the specific requirements of the 3 different examiners and their respective art units to resolve the 3 pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUR, GURPREET | 1 | 65.2% | +35.9% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780658 | Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors | MIANO, JOSEPH PAUL | 226d overdue |
| 18572665 | CONDUCTOMETRIC SENSOR FOR DETECTING A NUCLEIC ACID AND A METHOD FOR THE DETECTION THEREOF | KAUR, GURPREET | 127d overdue |
| 18013729 | NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN ACUTE MYELOID LEUKEMIA | STEVENS, MARK V | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780658 | Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors | MIANO, JOSEPH PAUL | 226d overdue |
| 18572665 | CONDUCTOMETRIC SENSOR FOR DETECTING A NUCLEIC ACID AND A METHOD FOR THE DETECTION THEREOF | KAUR, GURPREET | 127d overdue |
| 18013729 | NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN ACUTE MYELOID LEUKEMIA | STEVENS, MARK V | 20d |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 1613 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572665 | CONDUCTOMETRIC SENSOR FOR DETECTING A NUCLEIC ACID AND A METHOD FOR THE DETECTION THEREOF | KAUR, GURPREET | 1759 | §102§103 | Final Rejection | 127d overdue | Pending | Dec 20, 2023 |
| 18013729 | NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN ACUTE MYELOID LEUKEMIA | STEVENS, MARK V | 1613 | §103§112Other | Final Rejection | 20d | Pending | Dec 29, 2022 |
| 17780658 | Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors | MIANO, JOSEPH PAUL | 1631 | §103§112Other | Final Rejection | 226d overdue | Pending | May 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial